PharmaLex to open new office in France

Published: 12-Oct-2016
Regulatory Finance

The office opening in Paris, France, gives PharmaLex the opportunity to extend its local reach in one of the key worldwide markets


As of 26 September, 2016, the PharmaLex Group, the leading specialist provider of development consulting, regulatory affairs and pharmacovigilance, has opened a new office in Paris, France.

With this office establishment, the PharmaLex Group is now able to provide its extensive service portfolio to French customers, ensuring local presence and cultural fit to its clients.

The new subsidiary will be co-led by Ms Sophie Guillaume, General Manager and Mr Patrick Larcier, PharmD, MBA, Senior Director, Drug Development and Vigilance. Together the two of them bring along more than 25 years of industry and consulting experience in building, structuring, growing and managing teams. Furthermore, Mr Larcier has profound global knowledge and expertise in regulatory matters, vital to the pharmaceutical industry.

'Together with Patrick Larcier, I am excited to have planted the seed for PharmaLex in France. We will grow our local presence in close co-operation with our international colleagues, allowing us to provide highest standards of quality of all services from the very beginning,' said Sophie Guillaume.

'For the pharmaceutical industry, France plays a significant role on an international level. It is of great importance and strategic interest to be able to service this highly thriving market,' highlights Dr Thomas Dobmeyer, one of the CEO’s of the PharmaLex Group.

His counterpart, Dr Tilo Netzer, added: 'With Patrick and Sophie, we are happy to welcome senior executives strengthening our international team. Patrick is a key expert for the design and implementation of consulting and regulatory services at all stages of clinical development for complex and innovative medicinal products.'

The PharmaLex Group now has more than 500 employees, with 19 offices in 13 countries and more than 550 satisfied clients worldwide.

  • Companies:
  • PharmaLex
See more

You may also like

Regulatory

The right validation model: practical considerations and applications

Read more
It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
  3. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  4. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  5. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

The right validation model: practical considerations and applications

It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
Drug Delivery

PharmaLex reveals intention to merge with Cpharm

The merger plan is an important step to expanding PharmaLex’s footprint in Australia and New Zealand through Cpharm’s expert capabilities
Regulatory

European Commission adopts proposal to delay MDR deadlines

With thousands of outstanding conformity assessments for medical device certification under the Medical Device Regulation and limited capacity to manage these within the transition period, concerns about widespread product shortages in the EU market have been growing
Regulatory

Investment, outsourcing and globalisation: key trends for 2023

The start of 2023 has been challenging for the pharmaceutical industry. Economic constraints in Europe and the United States, staffing shortages, an increasingly complex regulatory environment and heightened competition for funding is putting pressure on companies
Finance

PharmaLex expands Nordic footprint across key business units with DRA Consulting merger

Alliance strengthens long-held collaboration and builds on overall regulatory, quality and market access services while advancing digital expertise
Regulatory

PharmaLex extends reach in Asia with Ascent merger

Headquartered in Tokyo, Ascent employs staff across Asia, and provides country-specific knowledge mixed with strategic advice from a global perspective
Manufacturing

PharmaLex and Phlexglobal announce merger

Through the merger, the company’s regulatory information management system will be used to support PharmaLex’s overall offering
Subscribe now